Multiple myeloma has become the most common hematologic malignancy in the United States adult population with over 120,000 people living with the disease. Despite new and more effective treatments, multiple myeloma, unfortunately, remains largely incurable with relapse and disease progression still common.
Dr. Ola Landgren Chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Cornell Medical College discusses advances in the field of immunotherapy for relapsed refractory multiple myeloma (RRMM). He discusses different treatment modalities and their unique strengths and limitations which have shown high antimyeloma activity that may address a critical unmet need in heavily pretreated and refractory patients. Dr. Landgren indicates that future studies will help identify optimal combinations and sequencing of different immunotherapies.
1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
This activity is intended for hematologists-oncologists, nurse practitioners, nurses, and other healthcare professionals.
This activity is supported by an independent educational grant from bluebird bio, Legend Biotech and Sanofi Genzyme.